生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Prilenia Names Jina Swartz, M.D. Ph.D., as Chief Medical Officer
2024-04-03
·
BioSpace
高管变更
快速通道
孤儿药
临床3期
-- Expansion of leadership team aligned with planned first global regulatory submission for approval for
pridopidine
for
Huntington’s disease
and preparation for commercialization -- NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--
Prilenia Therapeutics B.V.
, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of
neurodegenerative diseases
and
neurodevelopmental disorders
, today announced the appointment of Dr. Jina Swartz, M.D. Ph.D., as its first Chief Medical Officer (CMO). In this role, Jina will lead all clinical development and medical affairs activities at
Prilenia
. This press release features multimedia. View the full release here: Jina Swartz, M.D. Ph.D., Chief Medical Officer at
Prilenia
(Photo: Business Wire) Jina has more than 30 years’ experience in both academic neurology practice and in global drug development at leading pharmaceutical companies and joins
Prilenia
from Exciva, a neurodegeneration-focused biotech, where she was Chief Medical Officer. Previously, Jina served as Therapeutic Area Head of Neuroscience in Global Clinical Drug Development at
Merck and Co.
Renowned within both research and industry circles, Jina is active in several important neurology and neurodegeneration associations including the European Brain Council and the European Federation of Neurological Associations. She also was recently elected to the Fellowship of the Academy of Medical Sciences for her expertise in
neurodegenerative disorders
and neuropsychiatric drug development. “Jina joins
Prilenia
during an important phase of the Company’s growth. We recently announced plans to submit
pridopidine
for regulatory review in Europe for
Huntington’s disease (HD)
and to commence a pivotal, global Phase 3 study in
amyotrophic lateral sclerosis (ALS)
. Jina, in our newly created CMO role, will be a key leader as we advance these important initiatives,” said Dr. Michael R. Hayden, CEO of
Prilenia
. “Jina’s deep expertise as a thought leader, clinician treating
neurodegenerative diseases
and leader in global drug development is perfectly matched to our goal of changing the therapeutic landscape in HD and
ALS
.” “This is such an exciting time to be joining
Prilenia
and to help advance the Company’s mission to develop new therapeutic options for people living with
neurodegenerative diseases
like HD and
ALS
,” said Jina Swartz, M.D. Ph.D., Chief Medical Officer of
Prilenia
. “We have a remarkable opportunity, with
pridopidine
, to positively impact the lives of those living with these devastating diseases where progression has proven difficult to slow thus far. I believe that
Prilenia
is on the cusp of changing that paradigm.” Jina completed her Doctorate at the
University of Cambridge
, where her thesis focused on the exploration of molecular mechanisms of
neurodegeneration
in
Huntington's disease
and trinucleotide disorders. About
Pridopidine
Pridopidine
(45 mg twice daily) is an oral, highly selective and potent investigational
S1R agonist
S1R
agonist that has exhibited a safety and tolerability pro to placebo in clinical studies to date. The safety dataset includes approximately 1,700 patients who have been on
pridopidine
for up to seven years. The
S1R
protein is highly expressed in the brain and spinal cord, where it regulates several key processes that are commonly impaired in various
neurodegenerative diseases
. Activation of the
S1R
by
pridopidine
stimulates multiple cellular protective pathways including enhancing autophagy, axonal transport, mitochondrial energy production and respiration, and restores calcium homeostasis. These effects are essential to neuronal function and survival, and lead to neuroprotective effects.
Prilenia
holds Orphan Drug designation for
pridopidine
in HD and
ALS
in the U.S. and EU. In addition,
pridopidine
has received Fast Track designation by the
U.S. Food and Drug Administration (FDA)
for the treatment of HD. About
Prilenia
Prilenia
is a clinical stage biotechnology company founded in 2018 focused on the urgent mission to develop novel therapeutics to slow the progression of
neurodegenerative diseases
and
neurodevelopmental disorders
. The initial focus of the company has been on HD and
ALS
.
Prilenia
is backed by a group of well-respected investors including: Forbion,
Morningside
,
Sands Capital
, SV Health Investors, Sectoral Asset Management,
Talisman
,
Amplitude Ventures
and the ALS Investment Fund. The Company is based in the Netherlands, Israel and Massachusetts in the U.S. For more information, visit and follow us on LinkedIn and Twitter. ©2024
Prilenia Therapeutics B.V.
For a copy of this release, visit
Prilenia
’s website at .
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Prilenia Therapeutics BV
Prilenia Therapeutics Development Ltd.
Merck & Co., Inc.
[+6]
适应症
亨廷顿舞蹈病
神经系统变性病
神经发育障碍
[+2]
靶点
TMBIM4
药物
普利多匹定
A1R agonists(Hengrui)
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务